Evidence map›Paper›PMID 41908146›Full record

ArticleNeuro-oncology advances

Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma,

Daniel H Lachance, Paul A Decker, Thomas M Kollmeyer, Kristen L Drucker, Corinne E Praska, Matthew L Kosel, AbdulLateef A Odukoya, Sani H Kizilbash, Muhammad Asad Maqbool, Shameel Shafqat and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Daniel H LachanceNeurology, Mayo Clinic Rochester, Minnesota.ORCID https://orcid.org/0000-0001-8653-2259
Paul A DeckerQuantitative Health Services, Mayo Clinic Rochester, Minnesota.
Thomas M KollmeyerMolecular Pharmacology and Experimental Therapeutics, Mayo Clinic Rochester, Minnesota.
Kristen L DruckerNeurosurgery Research, Mayo Clinic Rochester, Minnesota.
Corinne E PraskaAnatomic Pathology, Mayo Clinic Rochester, Minnesota.
Matthew L KoselQuantitative Health Services, Mayo Clinic Rochester, Minnesota.
AbdulLateef A OdukoyaLaboratory Medicine and Pathology, Mayo Clinic Rochester, Minnesota (C.M.I., R.B.J.); Radiation Oncology, Mayo Clinic Rochester, Minnesota.
Sani H KizilbashMedical Oncology, Mayo Clinic Rochester, Minnesota (S.H.K., E.G.).
Muhammad Asad MaqboolCancer Center, Mayo Clinic Rochester, Minnesota.
Shameel ShafqatCancer Center, Mayo Clinic Rochester, Minnesota.
William Oliver TobinNeurology, Mayo Clinic Rochester, Minnesota.
Ian F ParneyNeurologic Surgery, Mayo Clinic Rochester, Minnesota.
Terry C BurnsNeurologic Surgery, Mayo Clinic Rochester, Minnesota.
Evanthia GalanisMedical Oncology, Mayo Clinic Rochester, Minnesota (S.H.K., E.G.).ORCID https://orcid.org/0000-0001-8014-786X
Caterina GianniniAnatomic Pathology, Mayo Clinic Rochester, Minnesota.ORCID https://orcid.org/0000-0003-2757-6782
Rachel A VaubelAnatomic Pathology, Mayo Clinic Rochester, Minnesota.
Cris M IdaAnatomic Pathology, Mayo Clinic Rochester, Minnesota.
Robert B JenkinsAnatomic Pathology, Mayo Clinic Rochester, Minnesota.ORCID https://orcid.org/0000-0002-4049-694X
Jeanette E Eckel-PassowQuantitative Health Services, Mayo Clinic Rochester, Minnesota.ORCID https://orcid.org/0000-0002-6113-1114

Funding

UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMASR01CA230712 · NCI · MAYO CLINIC ROCHESTER · PI JENKINS, ROBERT B. · 2018 to 2022
$3.3M
Diagnosis of indeterminate brain lesions using MRI-based machine learning and polygenic risk modelsR01NS113803 · NINDS · MAYO CLINIC ROCHESTER · PI ECKEL PASSOW, JEANETTE E, TOBIN, W. OLIVER · 2020 to 2024
$3.1M
FDA HHS R01 FD007288NCI NIH HHS R01 CA230712NINDS NIH HHS R01 NS113803
6 · The paper itself

Abstract

Background: Glioblastoma Methods: 101 hGBM cases were matched to 109 mGBM cases by age, sex, year of diagnosis, and Results: Median time from first MRI to diagnosis was longer for mGBM versus hGBM (34 vs 7 days, Conclusion: mGBM with MRI enhancement may represent undersampled or early/evolving hGBM. mGBM that are non-enhancing, present with seizures, prolonged time to diagnosis, absent CDKN2A/B alteration or +7/-10 may represent other IDH-wildtype entities.

Indexed as

clinical and radiographic featuresmolecular glioblastoma IDH-wildtypesurvival

Identifiers

PMID41908146
PMCPMC13019146

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.